000			01937 a2200601 4500
005			20250517041323.0
264		0	_c20160413
008			201604s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2015.164 _2doi
040			_aNLM _beng _cNLM
100	1		_aGhobrial, I M
245	0	0	_aPhase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. _h[electronic resource]
260			_bLeukemia _cDec 2015
300			_a2338-46 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBortezomib _xadministration & dosage
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEverolimus _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aMyeloid Differentiation Factor 88 _xgenetics
650	0	4	_aReceptors, CXCR4 _xgenetics
650	0	4	_aRecurrence
650	0	4	_aRituximab _xadministration & dosage
650	0	4	_aWaldenstrom Macroglobulinemia _xdrug therapy
700	1		_aRedd, R
700	1		_aArmand, P
700	1		_aBanwait, R
700	1		_aBoswell, E
700	1		_aChuma, S
700	1		_aHuynh, D
700	1		_aSacco, A
700	1		_aRoccaro, A M
700	1		_aPerilla-Glen, A
700	1		_aNoonan, K
700	1		_aMacNabb, M
700	1		_aLeblebjian, H
700	1		_aWarren, D
700	1		_aHenrick, P
700	1		_aCastillo, J J
700	1		_aRichardson, P G
700	1		_aMatous, J
700	1		_aWeller, E
700	1		_aTreon, S P
773	0		_tLeukemia _gvol. 29 _gno. 12 _gp. 2338-46
856	4	0	_uhttps://doi.org/10.1038/leu.2015.164 _zAvailable from publisher's website
999			_c25041666 _d25041666